Catalyst Biosciences (NASDAQ:CBIO) Stock Attempts To Bounce Back: Time to Buy?
Catalyst Biosciences (NASDAQ:CBIO) gained 5% after presenting its first poster during the 2021 International Society for Thrombosis and Haemostasis virtual Congress. In the first poster, the company presented an animal model study investigating subcutaneous marzeptacog alfa’s SQ MarzAA) effect on tail vein transection bleeding ion FVII deficient rats.
The second poster highlighted the company’s work supporting dose escalation for Sq MarzAA in anticipated clinical studies. The third poster presented data leveraging clinical study simulation to support SQ MarzAA dose selection in children with Haemophilia A and B inhibitors. The last poster was about the study investigating injection site reaction mechanism by studying cutaneous cellular and proteomic changes following SQ DalcA administration in the in vivo minipig model and ex vivo human HypoSkin biopsy platform.
CEO Nassim Usman said the company’s scientific teams had developed a vast body of knowledge around DalcA and MarzAA. Usman said that they are delighted to present some of the findings at ISTH. In the coming months, CBIO is a stock to watch.
Market Reaction:
On Tuesday, CBIO stock gained 4.64% at $4.51 with more than 293k shares, compared to its average volume of 333k shares. The stock has moved within a range of $4.2600 – 4.5400 after opening the trade at $4.31. Over the past 52-week, the stock has been trading within a range of $4.0500 – 7.5500.
